Clinical Trial

GT719 Injection for Moderate to Severe Refractory Autoimmune Disease

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study is a prospective single-arm open-label clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in patients with moderate to severe refractory autoimmune disease. A total of 30 subjects will be enrolled in this study.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-14.
Status change: Not Yet Recruiting → Recruiting 2026-04-13
Trial Details
NCT Number NCT07132112
Lead Sponsor Grit Biotechnology
Collaborators: Affiliated Hospital of Nantong University
Conditions Auto Immune Disease
Enrollment 30 participants
Start Date 2025-10-28
Primary Completion 2028-08 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2026-04-16